Optimal Teicoplanin Trough Concentration With Therapeutic Drug Monitoring in Children: A Systematic Review and...

Area of Science:

• Pharmacology
• Pediatric Infectious Diseases
• Clinical Microbiology

Background:

• Teicoplanin is vital for treating severe Gram-positive bacterial infections.
• Optimal teicoplanin trough concentrations in pediatric patients lack clear guidelines.
• This study addresses the need for optimized teicoplanin monitoring in children.

Purpose of the Study:

• To establish the optimal teicoplanin trough concentration for pediatric patients.
• To correlate teicoplanin trough levels with treatment efficacy and safety outcomes.
• To inform pediatric dosing guidelines for teicoplanin therapy.

Main Methods:

• A systematic review and meta-analysis of 12 studies involving 830 pediatric patients.
• Analysis of teicoplanin trough concentrations at stepwise cutoffs (10-30 mcg/mL).
• Evaluation of treatment success rates, all-cause mortality, nephrotoxicity, hepatotoxicity, and thrombocytopenia.

Main Results:

• Trough concentrations below 10 mcg/mL significantly reduced treatment success (50.0% vs. 95.7% at ≥10 mcg/mL).
• Concentrations below 20 mcg/mL were associated with a decreased risk of nephrotoxicity (OR=0.21).
• No significant associations were found between 10-30 mcg/mL trough concentrations and hepatotoxicity or thrombocytopenia.

Conclusions:

• A teicoplanin trough concentration of 10-20 mcg/mL is suggested as optimal for pediatric patients.
• This range balances enhanced clinical success with reduced toxicity.
• Further prospective studies are recommended for validation.